Siqi Yuan

Siqi Yuan

Auto-generated profile, based on publicly available information

Siqi Yuan

Institute of Geriatrics, Affiliated Nantong Hospital of Shanghai University (The Sixth People’s Hospital of Nantong), School of Medicine, Shanghai University, Nantong, Jiangsu, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SYSiqi Yuan
Siqi Yuan
MJMengyu Jin
Mengyu Jin
YZYanyan Zhang
Yanyan Zhang
MZMengting Zhang
Mengting Zhang
MYMinjia Yuan
Minjia Yuan
JWJuan Wang
Juan Wang
Extracellular vesicles (EVs) are nanoscale, lipid bilayer-enclosed particles containing bioactive molecules that play crucial roles in tissue homeostasis. These vesicles regulate cellular functions via delivery of protein, lipid, and nucleic acid cargos to target cells, thereby orchestrating essential biological processes, including cellular proliferation, activation, angiogenesis, and immune responses. The past decade has witnessed unprecedented growth in research examining EV functions in cutaneous physiology and pathogenesis. Here, we describe the biogenesis, composition and cellular uptake of EVs, critically highlighting the therapeutic effects and potential mechanisms of EVs from mammalian, plant and bacterial cells in skin diseases, including skin wound healing, hair growth, aging, inflammatory diseases and cancers. In addition, we discuss clinical translation challenges and outline future research directions for advancing EV-based therapeutics in clinical dermatology.

22 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
The aberrant activation of FGFR acts as a potent driver of multiple types of human cancers. Despite the development of several conventional small-molecular FGFR inhibitors, their clinical efficacy is largely compromised because of low selectivity and side effects. In this study, we report the selective FGFR1/2-targeting proteolysis-targeting chimera BR-cpd7 that displays significant isoform specificity to FGFR1/2 with half maximal degradation concentration values around 10 nmol/L while sparing FGFR3. The following mechanistic investigation reveals the reduced FGFR signaling, through which BR-cpd7 induces cell-cycle arrest and consequently blocks the proliferation of multiple FGFR1/2-dependent tumor cells. Importantly, BR-cpd7 has almost no antiproliferative activity against cancer cells without FGFR aberrations, furtherly supporting its selectivity. In vivo, BR-cpd7 exhibits robust antitumor effects in FGFR1-dependent lung cancer at well-tolerated dose schedules, accompanied by complete FGFR1 depletion. Overall, we identify BR-cpd7 as a promising candidate for developing a selective FGFR1/2-targeted agent, thereby offering a new therapeutic strategy for human cancers in which FGFR1/2 plays a critical role.

1 August 2024
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
Pharmacokinetics parameters for BR-cpd7.

1 August 2024
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
Supplementary data: experimental section

1 August 2024
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
Figure S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity

1 August 2024
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
BR-cpd7 selectively degrades FGFR1/2. A-C, Immunoblot analysis of FGFR1/2/3 proteins in DMS114 (A), KATO III (B), and RT112/84 (C) cells treated with BGJ398, BR-cpd7 or BR-cpd7 NC at 10, 100 or 1000 nM for 24 h (n=3 replicates). D and E, HEK293T cells transfected with HiBiT-FGFR1/2/3 were treated with BGJ398 (D) or BR-cpd7 NC (E) for 36 h. FGFR1/2/3 protein levels were quantified with Nano-Glo HiBiT (n=3 replicates). (F) Immunoblot analysis of FGFR1/2/3 levels in DMS114 under comparable exposure time (n=3 replicates).